SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported encouraging data from an ongoing Phase 1 dose-escalation trial of XL147 in patients with solid tumors. XL147 is an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. Geoffrey Shapiro, MD, PhD, Director, Early Drug Development Center, at the Dana-Farber Cancer Institute, an investigator on the Phase 1 trial, will present the data in an oral session (Abstract #3500) beginning at 1:30 p.m. local time on Monday, June 1, 2009, at the American Society of Clinical Oncology Annual Meeting, which is being held May 29-June 2 in Orlando.
